• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

BB Pureos Bioventures LP

Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating, and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases. *

 

	Start	2018-02-01 established (approx)
	Group	Bellevue (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Escher, Dominik (Belleveue 201001 Managing Partner at BB Pureos Bioventures before ESBATech CEO + Founder)
	Person 2	Breiner, Klaus (BB Biotech Ventures + Vaximm 201605 Executive Chairman)
	Region	Guernsey
	Country	United Kingdom (GB)
	Street	Trafalgar Square Les Banques
	City	GY1 3QL St. Peter Port, Guernsey
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�: BB Pureos Bioventures. (9/23/20). "Press Release: Pureos Bioventures Closes First Fund with USD 170 Million". St. Peter Port, Guernsey & Küsnacht.
		Record changed: 2020-11-07

Advertisement

More documents for Bellevue (Group)

• [1] Corlieve Therapeutics S.A.S.. (11/2/20). "Press Release: Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions". Paris....
• [2] Araris Biotech AG. (10/22/20). "Press Release: Araris Biotech Completes CHF 15.2 Million Seed Financing Round". Zürich....
• [3] BB Pureos Bioventures. (9/23/20). "Press Release: Pureos Bioventures Closes First Fund with USD 170 Million". St. Peter Port, Guernsey & Küsnacht....
• [4] ImCheck Therapeutics S.A.S.. (9/15/20). "Press Release: ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)". Marseille....
• [5] NovoGo Therapeutics AG. (3/4/19). "Press Release: NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke". Zurich....
• [6] Cosmo Pharmaceuticals N.V.. (6/1/17). "Press Release: Cosmo Appoints New Head of Investor Relations". Dublin....
• [7] Bellevue Group AG. (12/2/16). "Press Release: Successful Launch of BB Healthcare Trust plc on the London Stock Exchange – Initial Issue Volume GBP 150 Million [Not for US]"....
• [8] Bellevue Asset Management AG. (9/5/14). "Press Release: Bellevue Group Acquires Adamant Biomedical Investments AG from Zürcher Kantonalbank and Strenghtens Its Leading Position in the Market for Healthcare Investing". Küsnacht....
• [9] BB Biotech AG. (2/20/14). "Press Release: Publication of 2013 Annual Report of BB Biotech AG"....
• [10] BB Biotech AG. (1/16/13). "Press Release: BB Biotech AG Earns After-tax Profits of CHF 368 Million in Fiscal 2012"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.